Anaphylactic Reactions to Isosulfan Blue Dye during Sentinel Lymph Node Biopsy for Breast Cancer

Tao Wang¹, De-bin Xu² and Zhen Liao³*

¹Department of Otolaryngology-Head & Neck Surgery, Sun Yat-sen University, China
²Departments of Thyroid and Neck Surgery, Nan Chang University, China
³Department of Operation Theater Services, Sun Yat-Sen University Cancer Center, China

*Both authors contributed equally

Abstract

Background: The sentinel lymph node biopsy is an alternative to axillary dissection for many breast cancer patients. Cases of anaphylactic reaction to the isosulfan blue dye used during sentinel lymph node biopsy have recently been reported. A retrospective study the incidence and severity of adverse reactions to isosulfan blue dye, we evaluated the incidence of severe anaphylactic reactions to isosulfan blue dye during the performance of sentinel lymph node biopsy for breast cancer at our institution.

Methods: A retrospective chart review study was enrolled consecutive 1456 patients for breast cancer performed at our institution. Sentinel lymph node biopsy was performed using both isosulfan blue dye and technetium-99m sulfur colloid. Cases of anaphylaxis were reviewed in detail.

Results: Overall, 12 (0.8%) of the 1456 patients had severe anaphylactic reactions. All 12 patients experienced cardiovascular collapse (profound hypotension and tachycardia) and skin reactions and patients required admission to an intensive care unit bed or equivalent setting for postoperative monitoring. No deaths or permanent disability occurred.

Conclusions: Prompt recognition and aggressive treatment of anaphylactic reactions to isosulfan blue are critical to prevent an adverse outcome. Lymphatic mapping with blue dye should be performed in a setting where personnel are trained to recognize and treat anaphylaxis.

Keywords: Sentinel lymph node; Biopsy; Anaphylaxis

Introduction

The Sentinel Lymph Node (SLN) biopsy has replaced Axillary Lymph Node Dissection (ALND) as the new standard of care in early breast cancer. Although dissection of the level I and II axillary lymph nodes is the gold standard for axillary staging, there are significant acute and chronic complications associated with the procedure [1,2]. Lymphatic mapping and SLN biopsy are now routinely used for staging of clinically lymph node negative patients with breast cancer. The SLN can be located by intra parenchymal injection of blue dye, either alone or in combination with a radiotracer. Isosulfan Blue (IB) is a patent dye, which, after subcutaneous or intra parenchymal injection, is absorbed by lymphoid tissue. It has been increasingly used for lymphatic mapping and for identification of sentinel lymph nodes [3]. Allergic or adverse reactions to IB dye have been reported in 0.06 and 2.7% of patients undergoing SLN biopsy in 11 single-institution studies representing 22803 patients, with a mean value of 0.71% [4]. Symptoms may range from mild (urticaria, erythema) to severe (pulmonary edema, hypotension, vascular collapse). Data on the incidence of severe anaphylactic reactions during the course of SLN biopsy for breast cancer are lacking. Given the substantial number of SLN biopsy currently being performed, even such a small risk of adverse reactions means that a significant number of individuals are at risk. To prospectively reduce the incidence and severity of adverse reactions to IB dye, we evaluated the incidence of severe anaphylactic reactions to IB dye during the performance of SLN biopsy for breast cancer at our institution.

Patient and Methods

Patient data

A retrospective chart review study was enrolled consecutive patients who were admitted to our
institution between January 2010 and December 2015 with initial diagnoses of breast cancer without any other previous treatment. Ethics approval was obtained from the Institutional Research Ethics Committee of the Medical Center. In total, 1456 patients with breast cancer were eligible for our study received a peritumoral injection with a 99mTc-labeled filtered sulfur colloid. All patients scheduled to receive IB dye. Lymphatic mapping and SLN biopsy were performed as previously described [5].

Results

Between January 1, 2010 and December 31, 2015, 1456 patients underwent lymphatic mapping and SLN biopsy. Overall, 12(0.8%) of the 1456 patients had severe anaphylactic reactions. All 12 patients experienced cardiovascular collapse (profound hypotension and tachycardia) and skin reactions. In each case, symptoms developed 15 to 30 minutes after injection of IB dye. All 12 patients required vigorous resuscitation with phenylephrine infusion, antihistamines, and rapid fluid administration. All 12 patients required admission to an intensive care unit bed or equivalent setting for postoperative monitoring. Three patients had second episodes of anaphylaxis during postoperative monitoring. These allergic reactions consisted of nausea and vomiting, symptoms more consistent with known side effects of narcotic medications than with true allergic reactions. Two patients had a history of true drug allergies: one had a history of mild allergic reactions to penicillin and sulfa drugs, with symptoms including urticaria and itching, and the other had a history of severe anaphylaxis upon exposure to intravenous iodine, with symptoms including bronchospasm and hypotension. No previous exposure to IB dye was reported by any of the 12 patients. No perioperative complications occurred in any of these patients.

Discussion

Lymphatic mapping and SLN biopsy are now routinely used for staging of clinically node-negative patients with breast cancer. IB is commonly used for lymph node dissection. As experience with SLN biopsy has expanded, reports of adverse reactions to IB dye used in mapping have increased. The incidence of allergic reactions to IB dye ranges from 0.8% to 2.7% [4]. Although anaphylaxis was reported with administration of a related dye as early as 1966, anaphylactic reaction to IB has been reported [7]. Montgomery identified three distinct patterns or grades of allergic reaction to the dye [6]. Grade 1 reactions were defined as urticaria or blue hives, pruritis, and/ or a generalized rash. Grade 2 reactions were defined as transient hypotension (systolic blood pressure ≤ 70 mmHg) not requiring vasopressors. Grade 3 reactions were defined as hypotension (systolic blood pressure <70 mmHg) requiring vasopressor support. Montgomery reported 39 adverse reactions to IB dye in a series of 2392 patients (1.6%) undergoing mapping for breast carcinoma. Nine (23%) of the adverse reactions were Grade 3 and 3(8%) were Grade 2 reactions [5]. In a previous report 7 (1.1%) of 639 patients injected with IB dye during lymphatic mapping for breast carcinoma had severe anaphylactoid reactions to the dye that required vigorous resuscitation [6]. All 7 had Grade 3 reactions characterized by cardiovascular collapse requiring vasopressors and admission to an intensive care unit or equivalent setting.

Our patient developed severe anaphylaxis after injection of IB. Low blood pressure required large doses of vasopressors over the first several hours after the event. All patients required vigorous resuscitation with phenylephrine infusion, antihistamines, steroids, and rapid fluid administration. This protracted course of hemodynamic instability may be explained by a continuous systemic uptake of isosulfan dye from the injected site, as was demonstrated by green serum discoloration that lasted throughout the stay in the recovery room. Anaphylaxis represents an immediate type I hypersensitivity reaction, and isosulfan-induced hypersensitivity is an immunoglobulin E-mediated reaction. We could not detect that our patient had previous exposure to isosulfan antigen; however, isosulfan is triphenylmethane dye used in industry to color textiles, cosmetics, detergents, paints, and cold remedies [5]. Therefore, previous exposure to any of these products may have sensitized our patient.

There have been no deaths reported as a result of these systemic reactions. The majority of affected patients stay 24 hours after the procedure. Series have been reported on the use of methylene blue as a substitute for IB [8]. Methylene blue may prove to be less allergenic than IB and therefore remains an intriguing possibility that warrants clinical investigation. Several studies have compared the efficacy of identification of the sentinel node using blue dye to the combination of blue dye and lymphoscintigraphy. In the literature reviewed, no study compared lymphoscintigraphy alone to blue dye, or to a combination of the two. To date there have been no reported allergic complications related to the injection of radioactive isotopes in lymphatic mapping. A well-designed prospective study comparing lymphoscintigraphy alone to the combination may provide evidence on the costs and benefits of using IB. As without any perioperative complication, prevention is often the best management. Perhaps skin testing in these patients will elicit a common antigen or substance that can be eliminated or avoided. Also, identification of people sensitive to the IB dye would allow proper preparation and precautions in these patients to eliminate or limit the extent of their response. Even if we are unable to prevent or eliminate this problem, knowledge of this complication can provide patients with better informed consent and allow breast physicians to be more prepared for these potentially serious reactions.

As its use permeates medicine, more of these allergic reactions should be expected. Although no deaths have been reported and the symptoms and manifestations are reversible, in our study 0.8% is a significant risk of occurrence. Until a better alternative is proven, high suspicion, early recognition, and appropriate clinical management are recommended. The first line of therapy involves the discontinuation of anesthetic agents, administration of 100% oxygen, rapid infusion of large amounts of intravenous fluids, and prompt administration of phenylephrine (0.1 to 0.3 mg intravenously given over 10 minutes). The second line of therapy includes H1-blockers (diphenhydramine hydrochloride 50 mg intravenously) and corticosteroids (methylprednisolone 125 mg intravenously). For refractory hypotension in patients receiving beta blockers, glucagon (1-mg ampule) constitutes a third line of treatment.

We chose to use a phenylephrine infusion instead of an epinephrine infusion because of the absence of any changes in airway pressure and because of the presence of sinus tachycardia (which improved after initiating phenylephrine). It is worthwhile mentioning that the stress dose of steroids failed to prevent the anaphylactic response to isosulfan. However, preoperative prophylaxis may be reduced the severity but not the overall incidence of adverse reactions to IB dye [9].

In breast cancer, the combination of IB dye and a radiotracer has
been shown to markedly increase the sensitivity of this procedure. Therefore, we currently advocate the use of IB dye in lymphatic mapping for breast cancer.

**Conclusion**

As SLN biopsy rapidly becomes the standard of care for identifying nodal metastases in women with breast cancer, the questions that now face surgeons relate to optimal technique and safety. Nonetheless, anaphylactic reactions to IB dye during the course of SLN biopsy for breast cancer, although their incidence is relatively low, could have serious consequences. As part of the informed consent process, patients should be informed of this potentially life-threatening allergic reaction. At a time when so called minimally invasive procedures such as SLN biopsy are shifting towards more cost-effective ambulatory settings, it becomes paramount that the personnel involved in the performance of these procedures be familiar with potential reactions and be prepared to immediately recognize and treat anaphylaxis. Surgeons must know that severe reactions to IB may occur, recognize them early, and be prepared to treat anaphylaxis. However, a larger-scale study on similar lines should be carried out investigating the molecular basis of these adverse reactions.

**References**